Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that GlaxoSmithKline (NYSE: GSK) was granted marketing authorization from the European Commission (EC) for Revolade® (eltrombopag) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP). Eltrombopag is indicated for adult chronic ITP splenectomized patients who have not responded (are refractory) to other treatments, such as corticosteroids and immunoglobulins…

Read more:
Ligand Announces Approval For Revolade(R) In Europe

You may also like:

• Frost & Sullivan Lauds Positron Corporation For Cardiac-Focused PET Molecular Imaging Scanner Attrius™
• Risk Stratification Imperative To Treatment Selection In Patients With AML
• Presbia’s Flexivue™ Micro-Lens Receives European Market Approval
• EDGE Medical Devices Launches Plasma Flat-Panel Digital Radiography Detector And Universal Retrofit Kit
• Afinitor(R) (everolimus) Now Licensed In UK For Advanced Kidney Cancer Patients After Failure Of First Line Vascular Targeted Therapy(1, 2)
• Human Genome Sciences And GlaxoSmithKline Announce Positive Phase 3 Study Results For BENLYSTATM In Systemic Lupus Erythematosus
• Cytheris Announces Publication Of Preclinical Study Showing Combination Of Interleukin-7 With Viral Vaccine Boosts Immunity To Tumors
• Study Finds Dramatic Increase In Metastatic Colon Cancer Survival
• Agendia To Present Multiple Predictive And Prognostic Studies On Breast And Colorectal Cancers At ASCO Annual Meeting
• Great Tastes And International Recipes That Reduce The Risk Of Heart Disease